Celera Files U.S. Regulatory Application with FDA

Celera Corporation CRA today announced that it has submitted a Premarket Approval Application to the U.S. Food and Drug Administration for its KIF6 Genotyping Assay, a new molecular In Vitro diagnostic test designed to detect a marker for risk of coronary heart disease independent of traditional risk factors and aid clinical evaluation when statin treatment is being considered.